Compare Morgan Stanley (MS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Morgan Stanley vs State Street SPDR S&P Biotech ETF — how do they compare? Morgan Stanley trades at $190.41 (market cap $294.39B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Morgan Stanley is far larger — about 29.1× State Street SPDR S&P Biotech ETF's market cap, and Morgan Stanley pays a 2.45% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Morgan Stanley for 92 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| MS | XBI | |
|---|---|---|
Market Cap | $294.39B | $10.11B |
Volume | 5,836,423 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $228.42 | $169.55 |
52-Week Low | $151.86 | $104.99 |
Typical Hold Time | 92 Days | 38 Days |
Enterprise Value | $660.04B | — |
Dividend Yield | 2.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Morgan Stanley (MS) trades at $189.71, down 0.66% with bearish technical signals despite strong fundamentals. The company has delivered three consecutive earnings beats with Q2 2026 EPS of $3.46 beating expectations by $0.57. Revenue growth accelerated to $66.0 billion in 2025 with net income margin expanding to 27.59%. Analyst consensus remains bullish with 55.77% buy ratings and a $229.25 price target representing 21% upside potential.
The investment case balances strong profitability and growth opportunities in wealth management and AI financing against concerning cash flow trends and technical weakness. While valuation appears reasonable at 15.14 P/E, investors face risks from volatile operating cash flows and rising debt levels. The stock offers attractive upside to analyst targets but requires monitoring of capital markets recovery timing.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
